Table 1 Baseline characteristics
From: Cardiac function assessed by myocardial deformation in adult polycystic kidney disease patients
|  | Lower (better) strain GLS = <− 17.8% (n = 55) | Higher (worse) strain (GLS > -17.8%) (n = 55) | P Value |
|---|---|---|---|
Demographics | |||
 Age, years | 45.1 ± 12.4 | 47.2 ± 14.3 | 0.43 |
 Male gender, n (%) | 14 (25) | 34 (62) | < 0.001 |
Race, n (%) | |||
 Caucasian | 48 (87) | 44 (80) | 0.61 |
 African American | 5 (9) | 8 (15) |  |
 Asian | 2 (4) | 3 (5) |  |
Clinical data | |||
 Systolic Blood Pressure, mmHg | 124.3 ± 13.4 | 127.6 ± 15.3 | 0.24 |
 Diastolic Blood Pressure, mmHg | 76.0 ± 10.3 | 79.4 ± 9.7 | 0.08 |
 Estimated GFR, mL/min/1.73m2 | 66 [45–102] | 57 [36–80] | 0.12 |
 Microalbumin/creatinine ratio, mg/g | 20 [10–30] | 21 [12–59] | 0.27 |
 Ht-Indexed Total Kidney Vol, cm3/m | 819 [480–1304] | 1289 [738–1806] | 0.01 |
 BMI, kg/m2 | 27.3 ± 5.7 | 28.8 ± 4.7 | 0.13 |
 Fasting Glucose, mg/dL | 83.6 ± 9.0 | 87.8 ± 9.5 | 0.02 |
 HDL cholesterol, mg/dL | 53.0 ± 14.5 | 47.0 ± 12.2 | 0.02 |
 LDL cholesterol, mg/dL | 105.5 ± 33.3 | 106.2 ± 30.5 | 0.91 |
 Total Cholesterol, mg/dL | 178.5 ± 33.9 | 179.2 ± 40.4 | 0.92 |
 Triglycerides, mg/dL | 86 [64–112] | 96 [75–126] | 0.13 |
 Hemoglobin, g/dL | 12.5 ± 1.3 | 13.2 ± 1.3 | 0.01 |
 ACE Inhibitor, n (%) | 37 (69) | 37 (67) | 0.89 |
 Beta blocker, n (%) | 1 (2) | 13 (24) | 0.001 |
 Diuretic, n (%) | 5 (9) | 4 (7) | 0.74 |